GNPXGenprex Inc
GNPX
Genprex Inc14,829
Mkt Cap
$8.01MVolume
91,891.0052W High
$55.0052W Low
$0.8513PE Ratio
-0.03GNPX Fundamentals
Price
$0.8556Prev Close
$0.87Open
$0.8850D MA
$1.51Beta
1.47Avg. Volume
1.26MEPS (Annual)
-$17.40P/B
0.36Rev/Employee
$0.00$6.20
Genprex Receives Patent Grant from The Israel Patent Office for the Combination of Reqorsa Gene Therapy and PD-1 Antibodies to Treat Cancer
Genprex Receives Patent Grant from The Israel Patent Office for the Combination of Reqorsa Gene Therapy and PD-1 Antibodies to Treat Cancer Genprex Receives Patent Grant from The Israel Patent Office for the Combination of Reqorsa Gene Therapy and PD-1 Antibodies to Treat Cancer PR Newswire AUSTIN...
PR Newswire·11d ago
Genprex Collaborators to Present Positive Preclinical Data on Diabetes Gene Therapy for Type 2 Diabetes at the 2026 American Society of Gene and Cell Therapy Annual Meeting
Genprex Collaborators to Present Positive Preclinical Data on Diabetes Gene Therapy for Type 2 Diabetes at the 2026 American Society of Gene and Cell Therapy Annual Meeting Genprex Collaborators to...
PR Newswire·13d ago
Positive Clinical Data on Biomarkers in Patients Receiving Reqorsa Gene Therapy To Be Released at the 2026 ASCO Annual Meeting
Positive Clinical Data on Biomarkers in Patients Receiving Reqorsa Gene Therapy To Be Released at the 2026 ASCO Annual Meeting Positive Clinical Data on Biomarkers in Patients Receiving Reqorsa Gene...
PR Newswire·19d ago
Genprex Signs Sponsored Research Agreement to Study Biomarkers that May Predict Patient Response to Reqorsa Gene Therapy
Genprex Signs Sponsored Research Agreement to Study Biomarkers that May Predict Patient Response to Reqorsa Gene Therapy Genprex Signs Sponsored Research Agreement to Study Biomarkers that May...
PR Newswire·20d ago
Genprex Collaborators Present Positive Preclinical Data on the Use of Reqorsa Gene Therapy for the Treatment of Lung Cancer at the 2026 AACR Annual Meeting
Genprex Collaborators Present Positive Preclinical Data on the Use of Reqorsa Gene Therapy for the Treatment of Lung Cancer at the 2026 AACR Annual Meeting Genprex Collaborators Present Positive...
PR Newswire·21d ago
Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa Gene Therapy for the Treatment of Lung Cancer at the 2026 AACR Annual Meeting
Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa Gene Therapy for the Treatment of Lung Cancer at the 2026 AACR Annual Meeting Genprex Collaborators to Present...
PR Newswire·2mo ago
Genprex to Participate at BIO Europe Spring 2026
Genprex to Participate at BIO Europe Spring 2026 Genprex to Participate at BIO Europe Spring 2026 PR Newswire AUSTIN, Texas, March 10, 2026 AUSTIN, Texas, March 10, 2026 /PRNewswire/ -- Genprex, Inc...
PR Newswire·2mo ago
Genprex Strengthens Intellectual Property Portfolio with Japanese and EU Patents for Reqorsa Gene Therapy in Combination with Immunotherapies to Treat Cancer
Genprex Strengthens Intellectual Property Portfolio with Japanese and EU Patents for Reqorsa Gene Therapy in Combination with Immunotherapies to Treat Cancer Genprex Strengthens Intellectual Property...
PR Newswire·3mo ago
EGFR-NSCLC Market to Observe Stunning Growth at a CAGR of 9.6% During the Forecast Period (2025-2034) DelveInsight
EGFR-NSCLC Market to Observe Stunning Growth at a CAGR of 9.6% During the Forecast Period (2025-2034) | DelveInsight EGFR-NSCLC Market to Observe Stunning Growth at a CAGR of 9.6% During the Forecast...
PR Newswire·3mo ago
Genprex Announces Positive Preliminary Preclinical Data from Study of GPX-002 in Type 2 Diabetic Animal Studies
Genprex Announces Positive Preliminary Preclinical Data from Study of GPX-002 in Type 2 Diabetic Animal Studies Genprex Announces Positive Preliminary Preclinical Data from Study of GPX-002 in Type 2...
PR Newswire·4mo ago
<
1
2
...
>